Actively Recruiting
Regulatory Mechanisms of EGR2 and NLRP3 Inflammatory Pathways in Cognitive Impairment and Depressive-Anxiety-Like Behaviors Associated With Obstructive Sleep Apnea-Hypopnea Syndrome
Led by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2025-08-13
1000
Participants Needed
1
Research Sites
62 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the molecular mechanisms behind cognitive and mood problems linked to obstructive sleep apnea-hypopnea syndrome (OSAS), a condition where repeated airway blockages during sleep cause low oxygen levels and inflammation. This study includes children aged 2 to 18 and adults over 18 with OSAS, as well as healthy volunteers matched by age and sex. The goal is to understand how inflammation-related genes EGR2 and NLRP3 may influence brain changes related to memory, attention, anxiety, and depression in OSAS patients. Participants will undergo clinical assessments including ENT exams for children and overnight sleep studies for adults. Biological samples such as blood, saliva, and for some adults, small fat tissue biopsies during surgery will be collected. These samples will be analyzed to measure gene expression and inflammatory markers. Researchers will then correlate these molecular findings with sleep quality, cognitive function, and mood scores to create predictive models using machine learning. Throughout the study, participants will complete questionnaires about sleepiness, mood, and cognition. Children will receive physical exams including nasal endoscopy and X-rays, while adults have polysomnography. Blood and saliva samples will be processed for various laboratory tests. The main outcome is to measure EGR2 and NLRP3 levels in different tissues from July 2025 to September 2026. The study aims to identify who may be at higher risk for cognitive or mood disturbances related to OSAS.
CONDITIONS
Brief Title
EGR2 and NLRP3 Pathways in Obstructive Sleep Apnea-Related Cognitive and Mood Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children aged 2 to 18 years with obstructive snoring or sleep apnea features on initial ENT outpatient screening
- Adults over 18 years with suspected obstructive sleep apnea syndrome presenting with chronic snoring, witnessed apneas, or daytime sleepiness
- No severe chronic heart, liver, kidney failure, psychiatric disorders, or pregnancy in adults
- Signed written informed consent by the participant or their legal guardian
- Not currently enrolled in any other registered clinical trial
You will not qualify if you...
- Presence of congenital craniofacial malformations
- Severe heart, lung, liver, or kidney failure, or major neurological disease
- Recent use of anti-inflammatory or other immunomodulatory medications
- Current psychiatric disorder or pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From July 2025 to September 2026
Participants provide blood and saliva samples for analysis of inflammatory pathway activity. Adults undergoing surgery may also provide a subcutaneous fat biopsy.
1 to 2 visits depending on participant group and procedures
Trial Site Locations
Total: 1 location
1
Shanghai Xinhua hospital
Shanghai, China
Actively Recruiting
Research Team
J
Jiang, PHD,MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here